Topiramate (lithium)

Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase[1][2][3].

Product Specifications

CAS Number

[488127-53-3]

Product Name Alternative

McN 4853 (lithium) ; RWJ 17021 (lithium)

UNSPSC

12352005

Target

Calcium Channel; Carbonic Anhydrase; GABA Receptor; iGluR; Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/topiramate-lithium.html

Solubility

10 mM in DMSO

Smiles

NS(OC[C@]1(OC(C)(C)O2)[C@@H]2[C@H](OC(C)(C)O3)[C@H]3CO1)(=O)=O.[Li]

Molecular Formula

C12H21LiNO8S

Molecular Weight

346.30

References & Citations

[1]Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46 (8) :1097-104.|[2]Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67 (15) :2231-56.|[3]Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115 (1) :53-7.